US OptionsDetailed Quotes
CRVS241220P12000
- 5.00
- 0.000.00%
15min DelayClose Dec 19 16:00 ET
0.00High0.00Low
5.00Open5.00Pre Close0 Volume0 Open Interest12.00Strike Price0.00Turnover0.00%IV-37.52%PremiumDec 20, 2024Expiry Date6.91Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.74Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Corvus Pharmaceuticals Stock Discussion
Sign in to post a comment
3
$Nukkleus (NUKK.US)$
day 2, though im making 1k+ from this NUKE everyday… im just covering loss from pharma… never gonna touch meds again else wld be up 6k+ hahahaha
day 2, though im making 1k+ from this NUKE everyday… im just covering loss from pharma… never gonna touch meds again else wld be up 6k+ hahahaha
3
5
scam stay away$Corvus Pharmaceuticals (CRVS.US)$
why everyone are leaving? i thought this is a promising clinical sign???
why everyone are leaving? i thought this is a promising clinical sign???
4
$Corvus Pharmaceuticals (CRVS.US)$ Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile
Data includes complete results from cohort 1 and initial results from cohort 2
Early exercise of common stock warrants from stockholder generates cash proceeds of approximately $12.7 million
Company to host conference call and webca...
Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile
Data includes complete results from cohort 1 and initial results from cohort 2
Early exercise of common stock warrants from stockholder generates cash proceeds of approximately $12.7 million
Company to host conference call and webca...
2
6
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Quantum-Si (QSI.US)$ $Linkage Global (LGCB.US)$ $Corvus Pharmaceuticals (CRVS.US)$ $Allakos (ALLK.US)$ $Richtech Robotics (RR.US)$ $CERo Therapeutics (CERO.US)$ $The Glimpse (VRAR.US)$ $Zeo Energy (ZEO.US)$ $Rezolve AI (RZLV.US)$ $Tonix Pharmaceuticals (TNXP.US)$ $Nukkleus (NUKK.US)$ $1847 Holdings (EFSH.US)$ $ParaZero Technologies (PRZO.US)$ $Vast Renewables (VSTE.US)$
📊⚡️📊
📊⚡️📊
15
2
$Corvus Pharmaceuticals (CRVS.US)$ Corvus Pharmaceuticals to Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
2
NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 months✅
$Wearable Devices (WLDS.US)$ PR 12/17:...
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 months✅
$Wearable Devices (WLDS.US)$ PR 12/17:...
58
18
2
$Corvus Pharmaceuticals (CRVS.US)$
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
BURLINGAME, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, will announce interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe ...
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
BURLINGAME, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, will announce interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe ...
1
2
$Corvus Pharmaceuticals (CRVS.US)$ Any news for this >10 % drop in 5 days?
$Corvus Pharmaceuticals (CRVS.US)$
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
Corvus Pharmaceuticals announced new preclinical data showing that soquelitinib, their lead ITK inhibitor, could potentially prevent lung damage, inflammation, and pulmonary hypertension caused by systemic sclerosis. The study used Fra-2 transgenic mice, which mirror human systemic sclerosis features. After seven weeks of oral soquelitinib...
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
Corvus Pharmaceuticals announced new preclinical data showing that soquelitinib, their lead ITK inhibitor, could potentially prevent lung damage, inflammation, and pulmonary hypertension caused by systemic sclerosis. The study used Fra-2 transgenic mice, which mirror human systemic sclerosis features. After seven weeks of oral soquelitinib...
1
No comment yet
liang wang199 : Don't trust any stock trading discussion groups. Stocks are a zero-sum transaction. The money you earn is the money lost by others. All online trading groups, especially WeChat groups, are designed to gather retail investors to operate in the same direction at the same time, while the group owner or the convener of the group will operate in the opposite direction, because only in this way can he make money. A healthy stock market requires everyone to have different trading strategies so that everyone has the opportunity to make money. If everyone follows the same trading strategy, then this trading strategy or reference indicator will become invalid because big funds will grab all retail investors and catch them all in one fell swoop. Some retail investors buy while others sell at the same time. As long as not everyone operates in one direction, the true price of the stock can be objectively reflected, and it will be difficult for the main funds to determine the direction of operation. Only then will retail investors have the possibility to make money from the main funds.
1ticker : gambling win or lose
Iwill TradeScared OP liang wang199 : I hear you what works for one doesn’t works for others , entire stock market most in a whole is full of scams small or big companies doesn’t matter , you shouldn’t trust anyone who doesn’t show their ins and outs in any stocks in any Community or chat rooms , most of people here follow analysts predictions to invest while they never reveals real entry and exit and their risk in play so no guaranteed success in making money , only solution is awareness and knowledge